抗精神病药物治疗对亨廷顿舞蹈症患者不自主运动及运动表现的影响。
Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.
作者信息
Girotti F, Carella F, Scigliano G, Grassi M P, Soliveri P, Giovannini P, Parati E, Caraceni T
出版信息
J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):848-52. doi: 10.1136/jnnp.47.8.848.
Abstract
Eighteen patients with Huntington's chorea were examined before and after neuroleptic treatment (haloperidol, pimozide, tiapride) to study the effect of such treatment on hyperkinesia and motor performance. Pimozide and haloperidol improved hyperkinesia; none of the drugs significantly affected motor performance. No correlation was found between the severity of hyperkinesia and motor performance scores, or between hyperkinesia and intelligence score, before and after therapy.
摘要
对18例亨廷顿舞蹈症患者在使用抗精神病药物（氟哌啶醇、匹莫齐特、硫必利）治疗前后进行检查，以研究此类治疗对运动亢进和运动表现的影响。匹莫齐特和氟哌啶醇改善了运动亢进；这些药物均未对运动表现产生显著影响。治疗前后，运动亢进的严重程度与运动表现评分之间，或运动亢进与智力评分之间均未发现相关性。
相似文献
1
Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.
J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):848-52. doi: 10.1136/jnnp.47.8.848.
2
Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea.
Curr Med Res Opin. 1984;9(5):329-38. doi: 10.1185/03007998409109601.
3
Tiapride in the treatment of Huntington's chorea.
Acta Neurol Scand. 1982 Jan;65(1):45-50. doi: 10.1111/j.1600-0404.1982.tb03060.x.
4
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):35-9. doi: 10.1136/jnnp.63.1.35.
5
Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
Eur Neurol. 1995;35(6):344-8. doi: 10.1159/000117158.
6
Neuroleptically induced dystonia in Huntington's disease: a case report.
Eur Neurol. 1989;29(1):39-40. doi: 10.1159/000116375.
7
Tiapride in 12 Huntington's disease patients.
J Neurol Neurosurg Psychiatry. 1985 Mar;48(3):292. doi: 10.1136/jnnp.48.3.292.
8
Hypokinesia in Huntington's disease.
Mov Disord. 1996 Jul;11(4):384-8. doi: 10.1002/mds.870110406.
9
[Dexamethasone therapy in Huntington chorea: preliminary results].
Riv Neurol. 1991 Nov-Dec;61(6):225-7.
10
Acute treatment of Huntington's chorea with lisuride.
J Neurol Sci. 1983 May;59(2):247-53. doi: 10.1016/0022-510x(83)90042-4.
引用本文的文献
1
Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.
Int J Mol Sci. 2025 Jun 27;26(13):6220. doi: 10.3390/ijms26136220.
2
Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington's Disease.
Biomedicines. 2022 Aug 15;10(8):1979. doi: 10.3390/biomedicines10081979.
3
The Many Faces of Huntington's Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review.
J Pers Med. 2022 Apr 6;12(4):589. doi: 10.3390/jpm12040589.
4
State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
Expert Opin Pharmacother. 2021 Jun;22(8):1015-1024. doi: 10.1080/14656566.2021.1876666. Epub 2021 Feb 8.
5
STF-62247 and pimozide induce autophagy and autophagic cell death in mouse embryonic fibroblasts.
Sci Rep. 2020 Jan 20;10(1):687. doi: 10.1038/s41598-019-56990-y.
6
An Update on the Treatment of Chorea.
Curr Treat Options Neurol. 2018 Sep 25;20(10):44. doi: 10.1007/s11940-018-0529-y.
7
Huntington's disease: the coming of age.
J Genet. 2018 Jul;97(3):649-664.
8
Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.
Neurotherapeutics. 2018 Jul;15(3):715-727. doi: 10.1007/s13311-018-0634-3.
9
Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases.
Metab Brain Dis. 2018 Aug;33(4):989-1008. doi: 10.1007/s11011-018-0214-6. Epub 2018 Mar 14.
10
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
Drugs. 2017 Jan;77(1):29-46. doi: 10.1007/s40265-016-0670-4.
本文引用的文献
1
Supplementary motor area and other cortical areas in organization of voluntary movements in man.
J Neurophysiol. 1980 Jan;43(1):118-36. doi: 10.1152/jn.1980.43.1.118.
2
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture.
Neurology. 1982 May;32(5):514-39. doi: 10.1212/wnl.32.5.514.
3
Basal ganglia disease.
Lancet. 1982 Nov 20;2(8308):1141-7. doi: 10.1016/s0140-6736(82)92797-0.
4
Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs.
Neurology. 1981 Oct;31(10):1333-5. doi: 10.1212/wnl.31.10.1333.
5
Simple and complex finger movement performance of patients with Parkinsonism before and after a unilateral stereotaxic thalamotomy.
J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):16-21. doi: 10.1136/jnnp.33.1.16.
6
A brief psychogeriatric assessment schedule. Validation against psychiatric diagnosis and discharge from hospital.
Br J Psychiatry. 1975 Nov;127:489-93. doi: 10.1192/bjp.127.5.489.
7
8
Pharmacology of Huntington's chorea. Personal experience.
Eur Neurol. 1977;16(1-6):42-50. doi: 10.1159/000114879.
9
Biochemical aspects of Huntington's chorea.
J Neurol Neurosurg Psychiatry. 1977 Jun;40(6):581-7. doi: 10.1136/jnnp.40.6.581.
10
Patterns of neuropsychological test performance in Huntington's disease.
J Nerv Ment Dis. 1975 Oct;161(4):276-9. doi: 10.1097/00005053-197510000-00007.
Zotero 插件